Gillard Baiba K, Lin Hu-Yu Alice, Massey John B, Pownall Henry J
Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, MS-A601, Houston, TX 77030, USA.
Biochim Biophys Acta. 2009 Dec;1791(12):1125-32. doi: 10.1016/j.bbalip.2009.07.004. Epub 2009 Jul 25.
Whereas hepatocytes secrete the major human plasma high density lipoproteins (HDL)-protein, apo A-I, as lipid-free and lipidated species, the biogenic itineraries of apo A-II and apo E are unknown. Human plasma and HepG2 cell-derived apo A-II and apo E occur as monomers, homodimers and heterodimers. Dimerization of apo A-II, which is more lipophilic than apo A-I, is catalyzed by lipid surfaces. Thus, we hypothesized that lipidation of intracellular and secreted apo A-II exceeds that of apo A-I, and once lipidated, apo A-II dimerizes. Fractionation of HepG2 cell lysate and media by size exclusion chromatography showed that intracellular apo A-II and apo E are fully lipidated and occur on nascent HDL and VLDL respectively, while only 45% of intracellular apo A-I is lipidated. Secreted apo A-II and apo E occur on small HDL and on LDL and large HDL respectively. HDL particles containing both apo A-II and apo A-I form only after secretion from both HepG2 and Huh7 hepatoma cells. Apo A-II dimerizes intracellularly while intracellular apo E is monomeric but after secretion associates with HDL and subsequently dimerizes. Thus, HDL apolipoproteins A-I, A-II and E have distinct intracellular and post-secretory pathways of hepatic lipidation and dimerization in the process of HDL formation. These early forms of HDL are expected to follow different apolipoprotein-specific pathways through plasma remodeling and reverse cholesterol transport.
肝细胞分泌主要的人类血浆高密度脂蛋白(HDL)蛋白载脂蛋白A-I,其存在形式有无脂型和脂化型,而载脂蛋白A-II和载脂蛋白E的生物合成途径尚不清楚。人类血浆以及源自HepG2细胞的载脂蛋白A-II和载脂蛋白E以单体、同二聚体和异二聚体形式存在。比载脂蛋白A-I亲脂性更强的载脂蛋白A-II的二聚化由脂质表面催化。因此,我们推测细胞内和分泌型载脂蛋白A-II的脂化程度超过载脂蛋白A-I,并且一旦脂化,载脂蛋白A-II就会二聚化。通过尺寸排阻色谱法对HepG2细胞裂解物和培养基进行分级分离显示,细胞内载脂蛋白A-II和载脂蛋白E完全脂化,分别存在于新生HDL和极低密度脂蛋白(VLDL)上,而细胞内载脂蛋白A-I只有45%被脂化。分泌型载脂蛋白A-II和载脂蛋白E分别存在于小HDL以及低密度脂蛋白(LDL)和大HDL上。同时含有载脂蛋白A-II和载脂蛋白A-I的HDL颗粒仅在从HepG2和Huh7肝癌细胞分泌后形成。载脂蛋白A-II在细胞内二聚化,而细胞内载脂蛋白E是单体,但分泌后与HDL结合,随后二聚化。因此,HDL载脂蛋白A-I、A-II和E在HDL形成过程中具有不同的肝脏脂化和二聚化的细胞内及分泌后途径。这些早期形式的HDL预计会通过血浆重塑和逆向胆固醇转运遵循不同的载脂蛋白特异性途径。